Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,626 signal articles · 64 in last 24h · 155,646 total before filter · latest 1h ago
64last 24h
847last 7d
141● bullish (7d)
89● bearish (7d)
214publishers
AllMacro196Earnings105M&A122Regulatory20Product21Analyst19
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
3 Reasons Investors Watch Skyward Specialty Insurance (SKWD)
StockStory4d agoneutral
3 Reasons Investors Watch Skyward Specialty Insurance (SKWD)

Skyward Specialty Insurance has had an impressive run over the past six months as its shares have beaten the S&P 500 by 17.7%. The stock now trades at $57.18, marking a 33.9% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Apple doesn't need to be in first place for AI. Here's why.
Yahoo Finance Video4d agoneutralVIDEO
Apple doesn't need to be in first place for AI. Here's why.

Apple (AAPL) stock hit a record high on Tuesday, driven by the latest fanfare over its foldable iPhone Duo. Today's Market Hang panel consists of Host Turney Duff, Yahoo Finance Executive Editor Brian Sozzi, Defiance ETFs CIO Sylvia Jablonski, Interactive Brokers chief strategist Steve Sosnick, and Gerber Kawasaki Wealth & Investment Management CEO Ross Gerber.

2 Reasons to Sell SPGI and 1 Stock to Buy Instead
StockStory4d agoneutral
2 Reasons to Sell SPGI and 1 Stock to Buy Instead

Over the last six months, S&P Global’s shares have sunk to $405.30, producing a disappointing 5.5% loss - a stark contrast to the S&P 500’s 16.2% gain. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.

Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Trefis4d agoneutral
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?

Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.

Should investors play AI bottlenecks over social media stocks?
Yahoo Finance Video4d agoneutralVIDEO
Should investors play AI bottlenecks over social media stocks?

Should investors bet more on the AI infrastructure bottlenecks than on other tech trends, such as social media? Today's Market Hang panel consists of Host Turney Duff, Yahoo Finance Executive Editor Brian Sozzi, Defiance ETFs CIO Sylvia Jablonski, Interactive Brokers chief strategist Steve Sosnick, and Gerber Kawasaki Wealth & Investment Management CEO Ross Gerber.